Drugs / M118
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00543400 | Sep 2007 → Apr 2009 | coronary artery disorder | Momenta Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M118 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00543400 ↗ |
| Action | Inhibit | “Potent activity against factor Xa and IIa” PMID 20368520 ↗ Apr 2010 |
| Modality | Other / unclassified | “M118 is a novel low-molecular-weight heparin” PMID 20368520 ↗ Apr 2010 |
| Route | Intravenous | “intravenous (IV) infusion” NCT00543400 ↗ |